Cyclacel Pharmaceuticals Gross Profit Over Time
| CYCC Stock | USD 0.36 0.01 2.86% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cyclacel Pharmaceuticals Performance and Cyclacel Pharmaceuticals Correlation. Cyclacel |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.40) | Revenue Per Share 0.044 | Quarterly Revenue Growth (0.99) | Return On Assets (1.03) | Return On Equity (5.71) |
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare Cyclacel Pharmaceuticals and related stocks such as Eliem Therapeutics, Ikena Oncology, and Ovid Therapeutics Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IKNA | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (35.7 M) | (16.1 M) | 13.6 M | (50.5 M) | (48 M) |
| OVID | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (255 K) | 12.6 M | 208.4 M | 1.5 M | (1.2 M) | (1.1 M) |
| CNTB | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (988 K) | (1 M) |
| EWTX | (123 K) | (123 K) | (123 K) | (123 K) | (123 K) | (123 K) | (123 K) | (123 K) | (123 K) | (123 K) | (185 K) | (272 K) | (538 K) | (1.7 M) | (1.6 M) |
| RZLT | (4.8 K) | (4.8 K) | (4.6 M) | (2.4 M) | (5.8 M) | (8.3 M) | (12.6 M) | 0.0 | (48 K) | (18 K) | (303 K) | (256 K) | (382 K) | (36 K) | (37.8 K) |
| PTIX | 0.0 | 0.0 | 85 K | 0.0 | 0.0 | 0.0 | (534) | (148) | (347) | (339) | (286) | (30.0) | (30.0) | (28.2 K) | (26.8 K) |
| TPST | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | (2 M) | (4.7 M) | (495 K) | (1.1 M) | (1.1 M) | (815 K) | (1.3 M) | (1.8 M) | (381 K) | (400.1 K) |
| MBRX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (6.2 K) | (18 K) | (68 K) | (185 K) | (285 K) | (260 K) | (222 K) | (127 K) | (133.3 K) |
| PULM | (7.9 M) | (7.9 M) | (7.9 M) | (6.2 M) | 0.0 | (6 M) | (9.3 M) | (9.9 M) | (12.8 M) | (4.9 M) | 12.6 M | (10.2 M) | 6.1 M | (8.2 M) | (8.6 M) |
| AKTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (10.2 K) | (39.8 K) | 0.0 | (42.4 K) | (19.2 K) | (8.9 K) | (4.1 K) | (3.7 K) | (4 K) | (4.2 K) |
| NXTC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (19.8 M) | 6.3 M | 22.4 M | (4.3 M) | (4.5 M) | (3.7 M) | (3.5 M) |
| CTMX | 888 K | 888 K | 888 K | 888 K | 5.1 M | 7.7 M | 15 M | 71.6 M | 59.5 M | 57.5 M | 100.4 M | 69.6 M | 53.2 M | 99 M | 53.9 M |
| SPRO | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | 335 K | 2 M | 4 M | 4.7 M | 9.3 M | 17.1 M | 47 M | 96.4 M | 101.2 M |
| ASMB | 0.0 | 0.0 | 0.0 | 0.0 | (24 M) | (65 K) | (80.3 K) | (35.2 M) | (57.9 M) | 16 M | 79 M | 5.8 M | (498 K) | (41.7 M) | (39.7 M) |
Cyclacel Pharmaceuticals and related stocks such as Eliem Therapeutics, Ikena Oncology, and Ovid Therapeutics Gross Profit description
Gross profit is a required income statement account that reflects total revenue of Cyclacel Pharmaceuticals minus its cost of goods sold. It is profit before Cyclacel Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| Cyclacel Pharmaceuticals | CYCC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.36
Check out Cyclacel Pharmaceuticals Performance and Cyclacel Pharmaceuticals Correlation. For information on how to trade Cyclacel Stock refer to our How to Trade Cyclacel Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Cyclacel Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.